Vitamin D and resveratrol in sarcopenic obesity: a systematic review highlighting the gap in phenotype-defined randomized controlled trials (opens in new tab)

BackgroundSarcopenic obesity (SO) is an inflammatory-metabolic condition characterized by the coexistence of excess adiposity and impaired skeletal muscle mass and function. Vitamin D and resveratrol modulate regulatory pathways implicated in SO pathophysiology, including NF-κB signaling, PGC-1α, mitochondrial regulation, and redox balance. Whether this mechanistic rationale has translated into phenotype-defined randomized clinical trials remains unclear.MethodsWe conducted a systematic dual-...